AXSM vs PBLS: fair value comparison
Axsome Therapeutics, Inc. and Parabilis Medicines, Inc. · Updated 2026-10-19
AXSM's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. PBLS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PBLS currently ranks higher by quality score.
| AXSM | PBLS | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $157.14 | $22.75 |
| 12-month range | $127.06–$255.17 | $22.75–$39.47 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #194 of 301 Healthcare | #192 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | Low |
| Margin trend | Expanding | — |
| Revenue growth | High | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AXSM fair value analysis · PBLS fair value analysis